Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2009
10/06/2009US7598259 mGluR1 antagonists as therapeutic agents
10/06/2009US7598258 Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
10/06/2009US7598257 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
10/06/2009US7598256 Pyrrolo [2,3-d] pyrimidine and their use as purinergic receptor antagonists
10/06/2009US7598255 Pyrimidine compounds as serotonin receptor modulators
10/06/2009US7598254 Substituted 1,3-thiazolo[5,4-d]pyrimidines as xanthine oxidase inhibitors
10/06/2009US7598253 Reverse-turn mimetics and methods relating thereto
10/06/2009US7598251 aminopyrazine derivatives; ROCK inhibitors; 3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine; antiinflammatory, antidiabetic, antiproliferative agents
10/06/2009US7598250 for treating neurodegenerative disease such as Alzheimer's disease
10/06/2009US7598249 4-(3,4-dibromo-benzyl)-piperazine-1-carboxylic acid pyridin-3-ylamide; fatty acid amide hydrolase (FAAH) activity; anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders such as multiple sclerosis
10/06/2009US7598248 E.g., 1-(1-methyl-2-morpholin-4-ylethyl)-6-bromoimidazo[4,5-b]pyrazin-2-ol; smooth muscle myosin or non-muscle myosin modulator; obesity, sarcopenia, wasting syndrome, frailty, cachexia, muscle spasm, post-surgical and post-traumatic muscle weakness, and neuromuscular disease
10/06/2009US7598247 Immunomodulating heterocyclic compounds
10/06/2009US7598246 A conjugated drug WITH ANTIBIOTIC, NUCLEOSIDE, ANTISENSE NUCLEIC ACID AND anti-cancer DRUGS CAPABLE OF RELEASING ANTIBIOTIC OR CYTOTOXIC COMPONENT UPON BINDING WITH BONE TISSUE; tissue-targeted therapy TREATING BONE CANCER AND INFECTION
10/06/2009US7598245 Pyruvate dehydrogenase kinase, c-KIT, cyclin-dependent kinases, Janus kinases, FLT3 kinase, AUR-2 kinase, tyrosine kinase; 1-(2-amino-4-pyridyl)-3-phenylaminotriazoles; combination therapy with antiallergens, immunomodulators, antiproliferative agents; Alzheimer's, Parkinson's, Multiple Sclerosis, asthma
10/06/2009US7598244 (S)-1-(3-ethoxy-1-methylpropyl)-3-[7-(3,4-methylenedioxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]urea; preventive and/or therapeutic agent for immunological rejection and/or graft versus host reaction in organ/bone marrow transplant, autoimmune disease, allergic disease and/or inflammatory disease
10/06/2009US7598243 inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases
10/06/2009US7598242 Compounds for the treatment of inflammatory disorders
10/06/2009US7598241 Carboxamide derivatives and their use as factor Xa inhibitors
10/06/2009US7598240 Matrix metalloproteinase inhibitors; 4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-carboxylic acid or its ethyl ester; chondrodegenerative diseases or inflammatory diseases such as arthrosis deformans
10/06/2009US7598239 Side effect reduction; antiproliferative agents; schizophrenia
10/06/2009US7598238 3-R-7-(phenylmethylene)-s-triazolo[3,4-b][1,3,4]-thiadiazine; fluorescent probes, antiproliferatives, anti-estrogenic, antimicrobial and antiviral agents; one-step, two-step syntheses; cancer; macular degeneration, psoriasis, arteriosclerosis or restenosis
10/06/2009US7598237 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
10/06/2009US7598236 Diazabicyclic central nervous system active agents
10/06/2009US7598235 Gonane ring substituted with hydroxy group and alkylamide derivatives used for achieving sustained systemic concentrations of therapeutic or prophylactic GABA(gamma-aminobutyric acid)analogs following administration to animals
10/06/2009US7598234 Steroid derived antibiotics
10/06/2009US7598233 Method for treating thrombosis
10/06/2009US7598232 Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders
10/06/2009US7598231 (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; modulators of the glucocorticoid receptor; asthma, dermatitis, inflammatory bowel disease, Alzheimer's disease, psychotic major depression
10/06/2009US7598230 Nucleotide mimics and their prodrugs
10/06/2009US7598228 Administering by direct injection into heart an expression vector comprising a nucleic acid sequence encoding AOP-1 operably linked to a promoter, wherein expression of nucleic acid sequence within cells of heart enhances production of AOP-1, protecting against myocardial cell death
10/06/2009US7598227 Modulation of apolipoprotein C-III expression
10/06/2009US7598226 Compositions and methods for the therapy and diagnosis of breast cancer
10/06/2009US7598224 Have a hydrophobic linker region and a heparin-binding region, useful as soluble biologics or as surface coatings for medical devices
10/06/2009US7598046 Use of Apolipoprotein B, Apolipoprotein E, fragments for diagnostic, detection, prognostic and therapeutic applications In bovine spongiform encephalopathy (BSE) and Creutzfeld-Jacob Disease
10/06/2009US7598045 Detection of the PC-LECTIN protein which correlates to the presence of an androgen-dependent prostate cancer cell; drug target and diagnostic marker for prostate cancer
10/06/2009US7598042 Early prostate cancer antigens (EPCA), polynucleotide sequences encoding them, and their use
10/06/2009US7597930 Substrate with a photocatalytic coating
10/06/2009US7597915 Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne
10/06/2009US7597901 System for delivering a composition to the nasal membrane and method of using the same
10/06/2009US7597899 Compositions comprising a combination of a free sphingoid base and ceramide and uses thereof
10/06/2009US7597889 Recombinant polypeptides and nucleic acids; Graft-vs-host disease, host-vs-graft disease, organ transplant rejection, bone-marrow transplant rejection, autoimmune vasculitis, arthritis or asthma
10/06/2009US7597886 Tumor necrosis factor-gamma
10/06/2009US7597885 Scaffolds; keratinocytes; biocompatability
10/06/2009US7597882 precursor containing a biocompatible liquid crosslinker polyethylene glycol with at least three activated acid functional groups that are strong electrophiles selected from succinimide, succinimidee ester, N-hydroxysuccinimide ester and maleimide; a ; covalently crosslink proteins; biomaterial; sealant
10/06/2009US7597277 Microparticles, microparticle production method, and microparticle production apparatus
10/06/2009CA2616580C Macrocyclic inhibitors of hepatitis c virus
10/06/2009CA2513809C Lipophilic derivatives of double-stranded ribonucleic acid
10/06/2009CA2505130C Pharmaceutical compositions
10/06/2009CA2485631C System and method for transparent early detection, warning, and intervention during a medical procedure
10/06/2009CA2438622C Compositions containing creatine and creatinine
10/06/2009CA2427617C Medicinal compositions for concomitant use as anticancer agent
10/06/2009CA2427195C Controlled release metformin compositions
10/06/2009CA2416927C Alpha-(1,4) linked glucose polymers containing oral compositions to alleviate or prevent tooth damage
10/06/2009CA2416194C Use of 2-methylene-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 to increase bone strength
10/06/2009CA2402431C 1,2,3,4-tetrahydroisoquinoline derivatives
10/06/2009CA2400461C Method for improving bone modeling and chondrocyte functioning in growing canines
10/06/2009CA2399971C Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator
10/06/2009CA2391430C Improved transdermal contraceptive delivery system and process
10/06/2009CA2378469C An oral solid composition comprising carbidopa, levodopa and entacapone
10/06/2009CA2376596C Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
10/06/2009CA2368095C Process for preparing inhibitors of nucleoside metabolism
10/06/2009CA2329350C Topical formulation comprising poloxamers and further microbicides
10/06/2009CA2328076C Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
10/06/2009CA2326348C Liposomal bupivacaine compositions and methods of preparation
10/06/2009CA2301377C N-aroylphenylalanine derivatives
10/06/2009CA2291048C Dehydration plant
10/06/2009CA2258924C Cftr channel activator compounds and pharmaceutical compositions containing same
10/06/2009CA2207779C Carcinoma treatment
10/06/2009CA2180479C Method for treatment of obesity using prolactin modulators and diet
10/06/2009CA2120626C Method for enhancing gut absorption
10/04/2009CA2661556A1 Gel formulation
10/04/2009CA2625304A1 Androgen receptor related methods for treating bladder cancer
10/02/2009CA2626292A1 Spray solution to treat athlete's foot
10/01/2009WO2009121069A2 Compositions and methods for the preparation of nanoemulsions
10/01/2009WO2009121042A1 Quinazoline derivatives and methods of treatment
10/01/2009WO2009121039A2 Administration of benzodiazepine compositions
10/01/2009WO2009121018A2 Opioid-nornicotine codrugs for pain management
10/01/2009WO2009121015A2 Methods of treating epithelial injury
10/01/2009WO2009120999A2 Use of an endoxifen prodrug for treatment of breast cancer
10/01/2009WO2009120919A2 Fenofibrate dosage forms
10/01/2009WO2009120914A1 Solid forms of an anti-hiv phosphoindole compound
10/01/2009WO2009120890A1 Dioxolane and dioxolanone fused indolobenzadiazepine hcv ns5b inhibitors
10/01/2009WO2009120885A2 Stabilizing lipid compositions for oral pharmaceutical agents
10/01/2009WO2009120881A1 Methods for improving lid margin and tear film function and treatment of lid margin desease using tetracycline family antibiotics
10/01/2009WO2009120874A2 INHIBITORS OF ANTIGEN RECEPTOR-INDUCED NF-кB ACTIVATION
10/01/2009WO2009120849A1 2-aryl- and 2-heteroarylthiazolyl compounds, methods for their preparation and use thereof
10/01/2009WO2009120841A1 Crystalline form of n-[[4-fluoro-2-(5-methyl-1h-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate
10/01/2009WO2009120826A1 2-aryl- and 2-heteroarylthiazolyl compounds, methods for their preparation and use thereof
10/01/2009WO2009120815A2 Therapeutic compositions and methods
10/01/2009WO2009120803A2 Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
10/01/2009WO2009120801A2 Ikki inhibitor therapies and screening methods, and related ikki diagnostics
10/01/2009WO2009120799A2 Methods of treating fibrotic disorders
10/01/2009WO2009120789A1 Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones
10/01/2009WO2009120745A1 Compounds for the treatment of hepatitis c
10/01/2009WO2009120735A1 Composition and method for transmucosal delivery of lofexidine
10/01/2009WO2009120733A1 Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
10/01/2009WO2009120720A1 Bridged heterocyclic compounds and methods of use
10/01/2009WO2009120717A2 Pyrido [3, 4-b] indoles and methods of use
10/01/2009WO2009120712A2 Compositions and methods for diagnosing and treating melanoma
10/01/2009WO2009120700A2 Inhibition of dcps
1 ... 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 2569 2570 ... 7860